FDA Says No to Regulating CBD Products as Supplements
How to regulate CBD supplements has become a pressing public health concern as the popularity of CBD supplements has exploded in the United States
How to regulate CBD supplements has become a pressing public health concern as the popularity of CBD supplements has exploded in the United States
It was originally approved in 2019 for the treatment of chronic pain.
Increased demand for ibuprofen oral suspension products due to a surge in 3 circulating viruses prompted the Agency to issue compounding guidance.
Decrease seen in rate and percentage of emergency department visits with opioid prescribed at discharge from 2017-2018 to 2019-2020
Authors recommend against clinical assessment alone when neuromuscular drugs are administered due to insensitivity of assessment
Significant decreases seen in the number of opioids prescribed, conversion to long-term opioid use seen
Diclofenac epolamine topical system is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
Small reductions in pain-related disability at three months for multidisciplinary biopsychosocial intervention, individualized postural therapy
More adverse dental outcomes seen with sublingual buprenorphine/naloxone compared with use of transdermal buprenorphine or oral naltrexone
The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021.